Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Gentian Diagnostics ASA Environmental & Social Information 2021

Nov 1, 2021

3604_rns_2021-11-01_469ae41d-53b3-4047-85b6-daec5766a1e5.pdf

Environmental & Social Information

Open in viewer

Opens in your device viewer

Background:

COVID-19 is associated with a wide range of manifestations. Especially in the emergency department (ED) it is vital to identify patients with a high risk for development of multi-organ failure. Calprotectin is a novel biomarker found in the intracellular compartment of cells of the granulomonocytic lineage We recently identified serum calprotectin levels to be an excellent predictor of multi-organ failure, need for intensive care unit (ICU) treatment and death2 .

1 .

Patients and Methods:

This analysis of an ongoing prospective controlled trial (CASCADE) was performed in the ED of the Charité – Universitätsmedizin Berlin Campus Benjamin Franklin from the beginning of February 2021. We have so far investigated a cohort of 70 patients, 43 with suspected infections and 27 with suspected non-infectious illness with 10 cases of COVID-19 proven by PCR.

ICU = Intensive Care Unit; n = Number of participants; PCR = Polymerase Chain Reaction

Results:

A total of 4 out of 10 COVID-19 patients were admitted to ICU and 1 patient died. Age median was 67 years (standard deviation 17.6 years) with 54% being male patients, in COVID-19 group of patients the median age was 48 (standard deviation 14.8 years) with 80% male patients. Calprotectin was measured in heparin plasma by PETIA method from Gentian AS, Norway. It was significantly higher in ventilated than in non-ventilated COVID-19 patients. Calprotectin was able to predict ICUadmission with an AUROC of 1.0 and performed better than procalcitonin.

Plasma calprotectin as a novel biomarker in COVID-19 in emergency medicine: Preliminary results of the ongoing CASCADE trial

Iris R. Betz 1 , Johannes Dickescheid 1 , Noa Galtung 1 , Aleksandra Havelka 3 , Kai Kappert 2 , Rajan Somasundaram1 and Wolfgang Bauer 1 1. Department of Emergency Medicine Campus Benjamin Franklin; 2. Institute of Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Charité Universitätsmedizin, Berlin, Germany; 3. Gentian AS, Moss, Norway

N Overall SARS-CoV2 Non SARS-CoV2 P-value
Number of patients [n (%)] 70 70 (100) 10 (14,3) 60 (85,7)
Demographics
Age [Mean (IQR)] 70 67 (51-78) 48 (41-60) 70 (53-80) 0,012
Sex female [n (%)] 70 31 (44,3) 2 (20) 29 (48,3) 0,097
Vital signs
BP syst. (mmHg) [Mean (IQR)] 70 135 (116-140) 133 (116-140) 137 (116-154) 0,557
Respiration rate (/min.) [Mean (IQR)] 70 16 (14-22) 18 (15-25) 16 (14-21) 0,385
Laboratory data
Creatinine (mg/dl) [Mean (IQR)] 70 0,94 (0,76-1,29) 0,93 (0,78-1) 0,94 (0,75-1,31) 0,808
Bilirubin (mg/dl) [Mean (IQR)] 55 0,59 (0,32-0,94) 0,6 (0,37-0,74) 0,58 (0,32-0,95) 0,904
Procalcitonin [µg/l] [Mean (IQR)] 49 0,17 (0,08-0,62) 0,1 (0,7-0,31) 0,18 (0,08-0,68) 0,275
CRP [mg/l] [Mean (IQR)] 64 27,2 (1,9-114,5) 70,3 (21,3-152,8) 15,9 (1,4-106,9) 0,144
WBC (/nl) [Mean (IQR)] 70 7,8 (4,5-12,7) 7,3 (6,2-8,1) 8,3 (3,5-12,9) 0,397
Platelets (/nl) [Mean (IQR)] 70 226 (174-285) 163 (152-211) 235 (192-290) 0,006
ICU admission [n (%)] 69 11 (15,7) 4 (40) 7 (11,7) 0,026
Mechanical ventilation [n (%)] 69 8 (11,4) 4 (40) 4 (6,7) 0,003
Comorbidities [n (%)] 70 58 (82,9) 7 (70) 51 (85) 0,247
90-days mortality [n (%)] 70 6 (8,6) 1 (10) 5 (8,3) 0,863

Tab. 1: Baseline characteristics of the recruited patients until May 2021. IQR = interquartile range; BP syst. = systolic blood pressure

2Bauer, W. et al. Outcome prediction by serum calprotectin in patients with COVID-19 in the emergency department. J Infect 82, 84–123 (2021). 3Rendeiro, A. F. et al. The spatial landscape of lung pathology during COVID-19 progression. Nature 593, 564–569 (2021).

in COVID patients. Calprotectin is outperforming Procalcitonin in the preliminary cohort in predicting admission to the ICU. n = 10

Conclusion and perspective:

Calprotectin is an easy to assess blood biomarker that is able to predict severe courses of disease in COVID-19 patients presented at the ED. The reason for this might be that especially the lung injury that is caused by macrophages and granulocytes is associated with poor outcome 3 . Macrophages and granulocytes release calprotectin which is highly involved in the pro-inflammatory response generated in COVID-19.

Fig.2: Calprotectin levels in COVID-19 (ventilated and non-ventilated) and infectious, non-COVID-19 ICU patients. A ventilated = 4, not ventilated = 6; B infectious non-COVID n = 60, COVID = 10; ** = p < 0.01, ns = non significant

Attribution 3.0 Unported License